# Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions.

> **NCT01218711** · PHASE1 · COMPLETED · sponsor: **Torrent Pharmaceuticals Limited**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Losartan Potassium and Hydrochlorothiazide Tablets

## Key facts

- **NCT ID:** NCT01218711
- **Lead sponsor:** Torrent Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218711, "Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01218711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*